Loading organizations...
§ Venture Capital · New York City, NY, USA
Growth equity and venture capital firm investing in life sciences, tech bio, and healthtech startups, focused on therapeutic-enabling technologies.
AVANT BIO is a New York-based early-stage and growth equity firm that invests in therapeutic-enabling technologies at the intersection of life sciences, tech bio, and healthtech. The firm focuses on providing institutional capital and operational oversight to revenue-generating startups developing specialized tools, services, and consumables that accelerate drug discovery and biomanufacturing processes. Through active board participation and hands-on strategic guidance, the venture capital firm helps its tech-enabled portfolio companies scale their commercial operations and exit to strategic buyers. The organization's investment strategy is executed by a specialized leadership team that includes key industry figures such as Operating Partner Reinhard Vogt and team member Peter Lee. Operating within the broader biotechnology sector, the firm targets late-stage venture opportunities that bridge technological innovation and practical therapeutic applications. AVANT BIO was officially founded in 2023 by Managing Partner Daniella Kranjac.
Key people at AVANT BIO.
Key people at AVANT BIO.
AVANT BIO is a New York-based early-stage and growth equity investment firm specializing in life sciences, tech bio, and healthtech sectors. Its mission is to invest in companies that innovate and revolutionize these fields by leveraging the convergence of advanced technologies and biological understanding to enable breakthrough therapeutic developments. The firm employs disciplined investment strategies backed by deep industry expertise and a broad network to accelerate portfolio company growth and value creation. AVANT BIO’s focus spans from early to late-stage investments, aiming to unlock the full potential of transformative advancements in life sciences and related technologies[1][3][5].
Founded in 2023, AVANT BIO was established by Daniella Kranjac, a pioneering woman leader in life sciences and private equity, alongside key partners including Peter Lee, Ole Henrik Bang-Andreasen, Reinhard Vogt, and Sebastien Latapie. The firm emerged to capitalize on the unprecedented innovation wave in life sciences driven by technological breakthroughs and unmet therapeutic needs. Since its inception, AVANT BIO has evolved to cover a broad investment mandate, combining institutional capital with insider access and expertise to identify high-potential companies often overlooked by other funds[1][3][5].
AVANT BIO rides the trend of convergence between biology and advanced technologies, a critical enabler for next-generation therapeutics and healthtech solutions. The timing is pivotal as breakthroughs in tech bio and healthtech address unmet medical needs and unlock new therapeutic modalities. Market forces such as increasing demand for innovative therapies, regulatory shifts favoring ethical and animal-free products, and growing investment interest in life sciences create a favorable environment. AVANT BIO influences the ecosystem by supporting companies that develop therapeutic enabling technologies and healthtech innovations, thus accelerating the pace of transformative therapies and setting new industry standards[1][3][4].
Looking ahead, AVANT BIO is positioned to deepen its impact by expanding its portfolio across emerging life sciences technologies and healthtech innovations. Trends shaping its journey include the rise of cell and gene therapies, advanced biologics, and sustainable, ethically sourced bioproducts. The firm’s influence is likely to grow as it continues to leverage its network and expertise to identify and scale breakthrough companies. AVANT BIO’s forward-looking strategy suggests it will remain a key player driving the next wave of innovation in life sciences, helping to bring tomorrow’s cures to market today[1][3][4].
